HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women
- 16 April 2015
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 87 (9) , 1578-1586
Abstract
High risk types of human papillomaviruses E6/E7 oncogenes and their association with tumor suppressor genes products are the key factors of cervical carcinogenesis. This study proposed them as specific markers for cervical dysplasia screening. The aim of the study is to compare the clinical and prognostic significance of HPV E6/E7 mRNA as an early biomarker versus HPV DNA detection and cytology in triage of woman for cervical cancer. The study group consists of 413 women: 258 NILM, 26 ASC‐US, 81 LSIL, 41 HSIL, and 7 unsatisfactory cytology. HPV4AACE screening, real‐time multiplex PCR and MY09/11 consensus PCR primers methods were used for the HPV DNA detection. The real‐time multiplex nucleic acid sequence‐based assay (NucliSENS EasyQ HPV assay) was used for HPV E6/E7 mRNA detection of the five most common high risk HPV types in cervical cancer (16, 18, 31, 33, and 45). The results show that HPV E6/E7 mRNA testing had a higher specificity 50% (95% CI 32–67) and positive predictive value (PPV) 62% (95% CI 46–76) for CIN2+ compared to HPV DNA testing that had specificity of 18% (95% CI 7–37) and PPV 52% (95% CI 39–76) respectively. The higher specificity and PPV of HPV E6/E7 mRNA testing are valuable in predicting insignificant HPV DNA infection among cases with borderline cytological finding. It can help in avoiding aggressive procedures (biopsies and over‐referral of transient HPV infections) as well as lowering patient's anxiety and follow up period. J. Med. Virol. 87:1578–1586, 2015.Keywords
This publication has 52 references indexed in Scilit:
- Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and ageJournal of Clinical Virology, 2014
- Clinical Performance of Human Papillomavirus E6 and E7 mRNA Testing for High-Grade Lesions of the CervixJournal of Clinical Microbiology, 2009
- Human Papillomavirus mRNA and p16 Detection as Biomarkers for the Improved Diagnosis of Cervical NeoplasiaCancer Epidemiology, Biomarkers & Prevention, 2008
- Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trialThe Lancet Oncology, 2008
- Liquid Compared With Conventional Cervical CytologyObstetrics & Gynecology, 2008
- HPV DNA testing in cervical cancer screening: From evidence to policiesGynecologic Oncology, 2006
- Immunohistochemical expression of p16INK4a is predictive of HR-HPV infection in cervical low-grade lesionsLaboratory Investigation, 2006
- Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population studyJournal of Clinical Pathology, 2005
- Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysisBritish Journal of Cancer, 2003
- Identification and Assessment Of Known And Novel Human Papillomaviruses by Polymerase Chain Reaction Amplification, Restriction Fragment Length Polymorphisms, Nucleotide Sequence, and Phylogenetic AlgorithmsThe Journal of Infectious Diseases, 1994